---
title: "Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275790059.md"
description: "H.C. Wainwright analyst Emily Bodnar has maintained a Buy rating on Agios Pharmaceuticals, setting a price target of $65.00. The positive outlook is driven by the early traction of Aqvesme (mitapivat) and strong commercial execution. Despite challenges from the REMS program, the initial prescription numbers indicate robust demand. Management's guidance on the thalassemia population and expectations for revenue growth support a significant sales ramp from 2Q–4Q 2026. Bodnar's analysis suggests a credible path for increasing mitapivat revenues, justifying the Buy recommendation on AGIO."
datetime: "2026-02-12T17:25:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275790059.md)
  - [en](https://longbridge.com/en/news/275790059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275790059.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275790059.md) | [English](https://longbridge.com/en/news/275790059.md)


# Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agios Pharma today and set a price target of $65.00.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Emily Bodnar has given his Buy rating due to a combination of factors that highlight the strength of Agios Pharma’s commercial execution and growth outlook. The early launch of Aqvesme (mitapivat) is showing robust traction, with a notable number of prescriptions written in roughly the first month despite the added complexity of a REMS program and the fact that many prescribers are new to mitapivat, underscoring strong underlying demand and favorable physician reception.

Moreover, management’s guidance on the addressable thalassemia population, combined with expectations for accelerating revenue recognition as more physicians and patients complete REMS and payers formalize coverage, supports a meaningful sales ramp from 2Q–4Q 2026. The firm’s revenue assumptions for Aqvesme, informed by a comparable launch trajectory seen with Filspari under a similar REMS construct, along with ongoing Pyrukynd sales, create a credible path to growing mitapivat revenues, which in turn underpins the positive view on valuation and justifies maintaining a Buy recommendation on AGIO.

Bodnar covers the Healthcare sector, focusing on stocks such as Agios Pharma, NovoCure, and Acrivon Therapeutics, Inc.. According to TipRanks, Bodnar has an average return of 11.0% and a 32.19% success rate on recommended stocks.

### 相關股票

- [Agios Pharmac (AGIO.US)](https://longbridge.com/zh-HK/quote/AGIO.US.md)

## 相關資訊與研究

- [Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction](https://longbridge.com/zh-HK/news/277548017.md)
- [Agios Pharma's PYRUKYND Approved In UAE For Alpha- And Beta-Thalassemia](https://longbridge.com/zh-HK/news/277470109.md)
- [Agios 2025 product revenue beats analyst estimates](https://longbridge.com/zh-HK/news/275748482.md)
- [Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline](https://longbridge.com/zh-HK/news/272590957.md)
- [Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways](https://longbridge.com/zh-HK/news/278387184.md)